Inflammatory arthritis and malignancy: A consensus report on risk assessment and clinical management based on a systematic review from the Turkish Society of Rheumatology Malignancy Study Group Türkiye Romatoloji Derneği - Romatoloji ve Malignite Çalışma Grubu enflamatuvar artrit ve malignite: Sistematik derlemeye dayalı risk değerlendirmesi ve klinik yönetim üzerine fikir birliği raporu
Journal of Turkish Society For Rheumatology, cilt.17, sa.3, ss.145-154, 2025 (Scopus, TRDizin)
- Yayın Türü: Makale / Derleme
- Cilt numarası: 17 Sayı: 3
- Basım Tarihi: 2025
- Doi Numarası: 10.4274/raed.galenos.2025.38257
- Dergi Adı: Journal of Turkish Society For Rheumatology
- Derginin Tarandığı İndeksler: Scopus, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.145-154
- Anahtar Kelimeler: biological therapies, cancer, disease modifying anti-rheumatic drugs (DMARDs), Inflammatory arthritis, malignancy, rheumatoid arthritis, spondyloarthritis
- Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Inflammatory arthritis (IA) is associated with an increased risk for certain malignancies, particularly lymphoma, due to underlying chronic inflammation. Conventional and targeted therapies used in IA modulate the immune system, raising concerns about the development of de novo malignancies or the progression of preexisting ones. Managing IA patients with a history of cancer remains one of the most challenging areas for clinicians, and while international guidelines exist, they generally focus on a narrower scope. This report is the first comprehensive consensus report from Türkiye to address the relationship between IA and malignancy across a wide spectrum, including baseline risk, treatment-related risk, management of patients with a history of cancer, treatment during active malignancy, premalignant lesions, and family history. Based on a systematic literature review, this report provides evidence-based, practical recommendations for specific scenarios frequently encountered in daily practice—such as cancer development during active treatment, premalignant lesions, and family history—which are often narrowly addressed in existing international guidelines. This report will help rheumatologists standardize decision-making processes regarding the coexistence of IA and malignancy, enabling them to take safer clinical steps. By promoting risk individualization and shared decision-making between patients and clinicians, it will strengthen personalized treatment approaches that ensure both effective control of rheumatic disease and oncologic safety.